Japanese Ministry of Health has approved NGENLA, a long-acting growth hormone jointly developed by Pfizer and OPKO. The drug is intended to treat short stature caused by growth hormone deficiency without closed epiphyses. NGENLA reduces the frequency of treatment from daily injections to one shot per week.